[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570437":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":29,"responsibleParty":57,"collaborators":19,"id":59,"slug":19,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":19,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":19,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":49,"whyStopped":19,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Second Affiliated Hospital of Guangzhou Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SIRT","EXPERIMENTAL","Patients will receive SIRT treatment",[13],"Procedure: SIRT",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","The patients will receive 1-2 sessions of SIRT.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Mingyue Cai, Dr.","CONTACT","+86-20-34156205","cai020@yeah.net",{"name":27,"role":23,"phone":24,"phoneExt":19,"email":28},"Kangshun Zhu, Dr.","zhksh010@163.com",[30,48],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The Second Affiliated Hospital of Guangzhou Medical University","NOT_YET_RECRUITING","Guangzhou","Guangdong","510260","China",{"type":38,"coordinates":39},"Point",[40,41],113.25,23.11667,{"lat":41,"lon":40},[44,46],{"name":27,"role":23,"phone":24,"phoneExt":19,"email":45},"zhksh010@126.com",{"name":27,"role":47,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"facility":31,"status":49,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":50,"geoPoint":52,"contacts":53},"RECRUITING",{"type":38,"coordinates":51},[40,41],{"lat":41,"lon":40},[54,55,56],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"name":27,"role":23,"phone":24,"phoneExt":19,"email":28},{"name":27,"role":47,"phone":19,"phoneExt":19,"email":19},{"type":58,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100570437",false,"NCT06707233","Y-90 SIRT for Unresectable HCC Larger Than 7cm","Y-90 Selective Internal Radiation Therapy for Unresectable Hepatocellular Carcinoma Larger Than 7cm: a Prospective, Single Arm Trial","Inclusion Criteria:\n\n* Pathologically confirmed or clinically diagnosed HCC\n* Unresectable HCC as assessed by a team of surgeons\n* The largest tumor size \\> 7 cm\n* Tumor recurrence after curative treatment (hepatectomy or ablation) is eligible for enrollment\n* At least one measurable intrahepatic target lesion\n* Appropriate for SIRT treatment after evaluation (including SPECT\u002FCT evaluation after arterial perfusion with 99Tc-MAA)\n* Child-Pugh score ≤ 7\n* ECOG PS ≤ 1\n* Adequate organ and hematologic function with platelet count ≥75×10\\^9\u002FL, leukocyte \\>3.0×10\\^9\u002FL, Neutrophil count ≥1.5×10\\^9\u002FL, haemoglobin ≥85 g\u002FL, ALT and AST≤5×ULN, creatinine≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds\n* life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Macrovascular invasion or extrahepatic metastasis\n* Decompensated liver function, including: ascites, bleeding from gastroesophageal varices, and hepatic encephalopathy\n* Organ (heart and kidneys) dysfunction\n* History of other malignancies\n* Uncontrollable infection\n* History of organ or cells transplantation\n* History of HIV\n* Pregnant or lactating patients","ALL","18 Years","75 Years",{"count":69,"type":70},33,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","This is a phase II clinical study to evaluate the efficacy and safety of SIRT in patients with HCC greater than 7 cm. After enrollment, patients received yttrium-90 selective internal radiation therapy. The primary endpoint of the study is objective reponse rate (ORR) as assessed by mRECIST. Secondary endpoints were: objective response rate (ORR) as assessed by RECIST 1.1, disease control rate (DCR), progression-free survival (PFS), time to response (TTR), duration of response (DOR), overall survival (OS), and safety (incidence and severity of adverse events).",[76],"Hepatocellular Carcinoma Non-Resectable",[78,79,80],"Hepatocellular Carcinoma","yttrium-90","selective internal radiation therapy","2025-01-26",{"date":83,"type":84},"2025-01-28","ACTUAL",{"date":86,"type":84},"2024-12-01",{"date":88,"type":70},"2027-11-30",{"name":5,"class":6},2]